| Empaveli — C3G or primary IC-MPGN | Maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor. | Therapy must be used for at least 12 weeks before Empaveli initiation; it must continue for reauthorization. Primary IC-MPGN is not covered after kidney transplant. |
| Enbrel — rheumatoid arthritis | Methotrexate, leflunomide, or sulfasalazine at maximally tolerated doses. | Minimum 3-month trial with failure, contraindication, or intolerance. |
| Enbrel — polyarticular juvenile idiopathic arthritis | Leflunomide or methotrexate at maximally tolerated doses. | Minimum 6-week trial with failure, contraindication, or intolerance. |
| Enbrel — plaque psoriasis | Topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor. | Minimum 30-day supply; topical corticosteroids may require 14 days. Failure, contraindication, or intolerance is required. |
| Enbrel — ankylosing spondylitis | One NSAID at a maximally tolerated dose. | Minimum 1-month trial with failure, contraindication, or intolerance. |
| Epidiolex — Lennox-Gastaut syndrome | Two formulary anticonvulsants, such as topiramate, lamotrigine, or valproate. | Trial, contraindication, or intolerance to two anticonvulsants is required. |
| Epidiolex — seizure indications | Two formulary anticonvulsants for Lennox-Gastaut syndrome. | The prerequisite applies to Lennox-Gastaut syndrome; it is not stated for Dravet syndrome or tuberous sclerosis complex. |
| Eucrisa — mild to moderate atopic dermatitis | One prescription-strength topical corticosteroid, such as triamcinolone acetonide or fluocinolone acetonide. | Trial and failure, contraindication, or intolerance, unless the affected area is sensitive, including the face, axillae, or groin. |
| Fasenra — severe eosinophilic asthma | Medium-dose or high-dose inhaled corticosteroid regimen with an additional controller, or the applicable ICS/LABA regimen. | Required controller therapy may be omitted when contraindicated or not tolerated; age-specific regimens apply. |
| Fasenra — HES | Corticosteroid therapy or cytotoxic/immunosuppressive therapy, such as hydroxyurea, cyclosporine, or imatinib. | Trial and failure, contraindication, or intolerance is required. |
| Glycopyrrolate | Concomitant PPI therapy; if PPIs are contraindicated or not tolerated, an H2-receptor antagonist. | The alternative pathway requires documented PPI contraindication or intolerance plus concomitant H2-receptor antagonist therapy. |
| Humira — rheumatoid arthritis | Methotrexate, leflunomide, or sulfasalazine. | At least a 3-month trial with failure, contraindication, or intolerance at maximally tolerated doses. |
| Humira — polyarticular juvenile idiopathic arthritis | Leflunomide or methotrexate. | At least a 6-week trial with failure, contraindication, or intolerance at maximally tolerated doses. |
| Humira — plaque psoriasis | Topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor. | Minimum 30-day trial; topical corticosteroids may require 14 days. Failure, contraindication, or intolerance is required. |
| Humira — ankylosing spondylitis | One NSAID at a maximally tolerated dose. | At least a 1-month trial with failure, contraindication, or intolerance. |
| Hyrnuo | Prior systemic therapy, such as chemotherapy. | Required for locally advanced or metastatic non-squamous NSCLC with an activating HER2/ERBB2 mutation. |
| Hyrnuo — prior systemic therapy | Prior systemic therapy, such as chemotherapy. | Prior therapy must be documented along with the qualifying NSCLC diagnosis and HER2/ERBB2 mutation. |
| Igalmi | At least two products used for acute agitation, such as olanzapine or ziprasidone. | Trial and failure, contraindication, or intolerance to at least two products; maintenance medication for the underlying disorder is also required. |
| Imbruvica — cGVHD | One or more lines of systemic therapy, such as corticosteroids including prednisone. | Trial and failure of one or more systemic therapy lines is required. |
| Inbrija | Two adjunctive therapy classes: MAO-B inhibitor, dopamine agonist, or COMT inhibitor. | Trial and failure, contraindication, or intolerance to two classes is required. |